[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pancreatic-cancer-non-resectable\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pancreatic-cancer-non-resectable":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,19,0,[8,41,69,96,128,166,195,222,251,271,296,322,342,362,380,408,434,462,488],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100643191","phase-1-safety-and-performance-of-a-novel-infusion-catheter-system-for-periintratumoral-gemcitabine-delivery-in-patients-with-pancreatic-cancer-100643191",false,"NCT07575191","Safety and Performance of a Novel Infusion Catheter System for Peri\u002FIntratumoral Gemcitabine Delivery in Patients With Pancreatic Cancer","A Single-center, Prospective, Non-randomized, Open, Pilot Study Evaluating the Safety and Performance of the Extroducer® Infusion Catheter System for Peri\u002FIntratumoral Gemcitabine Delivery in Patients With Unresectable Locally Advanced Pancreatic Cancer","Inclusion Criteria:\n\n* Able to comply with scheduled visits, treatment plan, able to undergo catheterization, imaging procedures, laboratory tests, required follow up visits, the filling out of required forms, and have the ability to understand and give written informed consent.\n* Voluntarily agrees to participate and has duly singed the Informed Consent Form.\n* Age 18 years or older.\n* Histologically confirmed, locally advanced pancreatic cancer.\n* Systemic treatment with IV chemotherapy for at least six months.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* The target tumor is a measurable tumor according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria v1.1 prior to initiating Extroducer® Gemcitabine treatment.\n* Stable disease or locally progressive disease without signs of metastatic disease as evaluated at a multidisciplinary tumor board within 4 weeks prior to first dose.\n* Locally Advanced Pancreatic Cancer not amenable to resection as evaluated at a multidisciplinary tumor board within 4 weeks prior to first dose.\n* Have acceptable organ and marrow function as defined below:\n\n  i. Absolute neutrophil count (ANC) ≥ 1500 cells\u002Fmm³ (1.5x109 cells\u002FL) ii. Hemoglobin ≥ 9.0 g\u002FdL iii. Platelets ≥ 100,000\u002FµL iv. Total bilirubin ≤ 2 × upper limit of normal (ULN). v. AST (Aspartate Aminotransferase) ≤ 3 × ULN. vi. ALT (Alanine Aminotransferase) ≤ 3 × ULN vii. Creatinine Within 1.5 x ULN OR Creatinine clearance ≥ 60 mL\u002Fmin for patients with creatinine levels above 1.5 x ULN.\n* Women of childbearing potential (defined as all women who are not surgically sterile or postmenopausal for at least 1 year prior to enrollment) must have a negative urine pregnancy test at enrollment and must agree to use a medically acceptable and highly effective contraception from enrollment until 6 months after final study treatment of Gemcitabine.\n* Male subjects who are planning to father a child (i.e., planning a pregnancy with a partner) during the clinical investigation.\n\n  i. Male subjects must agree to use highly effective contraception with female partners of childbearing potential during the clinical investigation and for 3 months after the last dose of Gemcitabine and must not donate sperm during this period.\n\nii. Acceptable methods include: a condom in addition to combined hormonal contraception, progestogen-only contraception, intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion in the female partner, or vasectomy of the male participant (confirmed azoospermia).\n\niii. Sexual abstinence is acceptable only if it is the subject's usual and preferred lifestyle; periodic abstinence and withdrawal are not acceptable.\n\nExclusion Criteria:\n\n* Participating in another clinical investigation which may interfere with the results in this clinical investigation per investigator judgement.\n* Inability to consent.\n* Pancreatic tumor is different from adenocarcinoma (e.g., neuroendocrine, metastases). Adenosquamous is allowed.\n* Cancer has spread to other organs or non-regional lymph nodes (Metastases).\n* Unknown stage or recurrent pancreatic cancer.\n* Patient contraindication to Gemcitabine treatments.\n* Patients in which iodine contrast is contraindicated.\n* Presence of structures that impede tumor access.\n* Concurrent or prior malignancy unless disease-free for ≥3 years, with exceptions for nonmelanoma skin cancer, carcinoma in situ of the cervix or bladder, or Gleason Grade \\\u003C 7 organ-confined prostate cancer. This may be subject to investigator's judgement based on individual patient circumstances and the nature of the malignancy.\n* Unmanaged concurrent illnesses, encompassing psychiatric conditions or challenging social circumstances, that, as per the investigator's judgment, could undermine compliance to the study protocols or pose an unacceptable risk to the patient.\n* Pregnant or nursing individuals.","ALL","18 Years",{"count":19,"type":20},9,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","This study is testing a new way to deliver the chemotherapy drug Gemcitabine in pancreatic tumors using the catheter Extroducer® Infusion Catheter System. The study will include patients with Locally Advanced Pancreatic Cancer that cannot be removed with surgery.\n\nPatients will receive four treatment sessions, given every two weeks, in which Gemcitabine is infused directly into or near the tumor. The study will test up to three increasing dose levels of Gemcitabine (200 mg, 400 mg, and 100 mg).\n\nThe study will enroll three groups of three patients each. After each group completes treatment, an independent safety committee will review the results to decide whether it is safe to move to the next dose per predefined study criteria.\n\nAfter finishing treatment, patients will be followed for six months. Each patient's total participation in the study will last about 8-9 months. The main goal of the study is to evaluate the safety and feasibility of this treatment approach.",[27],"Pancreatic Cancer Non-resectable","RECRUITING","2026-06-10",{"date":31,"type":32},"2026-06-12","ACTUAL",{"date":34,"type":32},"2026-04-29",{"date":36,"type":20},"2028-06",{"name":38,"class":39},"Smartwise Sweden AB","INDUSTRY",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":52,"conditions":53,"keywords":54,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":40},"100639757","phase-2-efficacy-of-stereotactic-body-radiotherapy-sbrt-combined-with-maintenance-therapy-compared-to-maintenance-therapy-alone-in-advanced-pancreatic-cancer-100639757","NCT07600268","Efficacy of Stereotactic Body Radiotherapy (SBRT) Combined With Maintenance Therapy Compared to Maintenance Therapy Alone in Advanced Pancreatic Cancer","Efficacy of Stereotactic Body Radiotherapy (SBRT) Combined With Maintenance Therapy Compared to Maintenance Therapy Alone in Advanced Pancreatic Cancer: A Multi-center, Randomized Controlled Phase II Clinical Trial","Inclusion Criteria:\n\n* Age 18 to 70 years old.\n* Histologically or cytologically confirmed diagnosis of pancreatic - adenocarcinoma.\n* No prior radiation therapy for pancreatic cancer.\n* At least one measurable lesion of the primary pancreatic tumor as per RECIST 1.1 criteria, eligible for SBRT.\n* Completion of first-line chemotherapy with stable disease (SD) or partial response (PR) after ≥4 months of treatment.\n* ECOG performance status of 0-2.\n* Expected survival of ≥3 months.\n* Adequate organ function within 14 days prior to enrollment:\n* Hemoglobin (Hb) ≥ 90 g\u002FL\n* Absolute neutrophil count (ANC) ≥ 1.5×10⁹\u002FL\n* Platelets (PLT) ≥ 75×10⁹\u002FL\n* Total bilirubin ≤ 1.5× ULN or direct bilirubin ≤ ULN\n* ALT\u002FAST ≤ 2.5× ULN\n* ALP ≤ 2.5× ULN\n* Serum creatinine ≤ 1.5× ULN or calculated creatinine clearance ≥ 40 mL\u002Fmin\n* Urine protein \\\u003C 2+ (if ≥2+ on dipstick, 24-hour urine protein must be \\\u003C 2g)\n* No use of systemic corticosteroids in the last 7 days prior to enrollment (physiological corticosteroid replacement is allowed).\n* Women of childbearing potential and men must use effective contraception during the study and for 12 months following treatment completion.\n* Voluntary participation with signed informed consent.\n* Ability to comply with the study schedule.\n\nExclusion Criteria:\n\n* Currently participating in any interventional clinical trial or having received other investigational drugs or devices within 4 weeks prior to enrollment.\n* Peritoneal metastasis.\n* Known active central nervous system (CNS) metastasis and\u002For carcinomatous meningitis.\n* Receiving systemic corticosteroid treatment within 7 days prior to enrollment (except for physiological doses).\n* Active, untreated hepatitis B (HBsAg positive and detectable HBV-DNA) or active hepatitis C infection (HCV antibody positive and detectable HCV RNA).\n* Pregnant or breastfeeding women.\n* Any severe or uncontrolled systemic disease, including:\n* QTc interval ≥ 480 ms\n* Unstable angina\n* NYHA class III-IV congestive heart failure\n* Arterial thromboembolism (MI, unstable angina, stroke, TIA) within 6 months prior to enrollment\n* Uncontrolled hypertension (systolic BP ≥ 150 mmHg, diastolic BP ≥ 90 mmHg)\n* Active pulmonary tuberculosis, severe infections, or other uncontrolled diseases\n* Active gastrointestinal perforation, fistula, or bowel obstruction.\n* Inadequately controlled diabetes (fasting blood glucose \\> 10 mmol\u002FL).\n* History of mental illness preventing compliance with treatment.\n* Active bleeding or significant coagulation abnormalities within the last 30 days.\n* Previous gastrointestinal perforation or other serious gastrointestinal conditions in the past 6 months.\n* Participation in other trials that may interfere with this study.","70 Years",{"count":50,"type":20},24,[24],"This is a Phase II, multicenter, randomized controlled trial to assess the efficacy of Stereotactic Body Radiotherapy (SBRT) in combination with maintenance therapy in patients with advanced pancreatic cancer. The aim is to compare the efficacy of SBRT combined with maintenance therapy versus maintenance therapy alone. The primary outcome is the overall survival (OS) of patients, with secondary endpoints including progression-free survival (PFS), response rates, and quality of life assessments. The study will involve patients with unresectable pancreatic adenocarcinoma who are receiving chemotherapy and have stable disease. The hypothesis is that SBRT, by improving local control, can enhance the benefit of ongoing maintenance therapy and lead to better overall survival outcomes in this patient group.",[27],[55,56,57,58],"Pancreatic cancer","Stereotactic Body Radiotherapy","maintenance therapy","chemotherapy","2026-05-19",{"date":61,"type":32},"2026-05-20",{"date":63,"type":32},"2025-08-14",{"date":65,"type":20},"2028-08-14",{"name":67,"class":68},"Shandong Cancer Hospital and Institute","OTHER",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":21,"phases":78,"briefSummary":80,"conditions":81,"keywords":84,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":40},"100528404","upfront-eus-cgncpn-vs-conventional-step-up-approach-for-inoperable-painful-pancreatic-cancer-100528404","NCT06160323","Upfront EUS CGN\u002FCPN vs Conventional Step up Approach for Inoperable Painful Pancreatic Cancer","Upfront Endoscopic Ultrasound-guided Celiac Ganglion Neurolysis Versus Conventional Step-up Approach for Patients With Painful, Inoperable Pancreatic Cancer","Inclusion Criteria:\n\n1. Age \\>= 18 years old\n2. Diagnosed to have inoperable pancreatic cancer\n3. Presence of tumor pain (centrally located, constant, with no other obvious cause) with a VAS \\>= 3\n4. Karnofsky performance status \\>= 60\n5. Planned for EUS examination and\u002For biopsy of the pancreatic tumor\n\nExclusion Criteria:\n\n1. Allergy to bupivacaine, or alcohol\n2. Potentially operable after neoadjuvant therapy\n3. Expected survival of less than 3 months\n4. Patient who is already on opioids for pain control\n5. Previous percutaneous or EUS-guided CGN\u002F CPN\n6. Recurrent pancreatic tumors after operation\n7. Uncorrectable coagulopathy\n8. Inability or unwillingness to provide informed consent",{"count":77,"type":20},94,[79],"NA","Patients with unresectable pancreatic cancer are often demoralized by intractable, persistent and incapacitating pain. It must be managed aggressively and strong opioids are recommended as the mainstay of treatment. However, patients develop opioid-related adverse effects. EUS-guided celiac plexus neurolysis (CPN) and celiac ganglion neurolysis (CGN) has been shown to provide high efficacy for pain control. The optimal timing, however, is in debate.",[27,82,83],"Tumor Pancreas","Pain Cancer",[27,85,86],"tumor pain","endoscopic ultrasound-guided celiac ganglion neurolysis","2026-05-04",{"date":89,"type":32},"2026-05-06",{"date":91,"type":32},"2023-11-10",{"date":93,"type":20},"2028-07-31",{"name":95,"class":68},"Chinese University of Hong Kong",{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":21,"phases":106,"briefSummary":107,"conditions":108,"keywords":115,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":40},"100360753","phase-2-tumor-subtypes-in-subjects-on-folfirinox-with-non-metastatic-pancreatic-cancer-100360753","NCT03977233","Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer","Impact of Tumor and Stromal Subtypes on Efficacy of Neoadjuvant FOLFIRINOX in Subjects With Non-Metastatic Pancreatic Cancer","Inclusion Criteria:\n\n* Written informed consent obtained to participate in the study and HIPAA authorization for release of personal health information.\n* Histologically or cytologically confirmed adenocarcinoma of the pancreas with no evidence of distant metastatic disease.\n* Subject has no evidence of co-morbidities precluding the potential to undergo surgical resection of PDAC as determined by surgical investigator.\n* Subjects must be willing to undergo a mandatory pre- and post-treatment EUS guided core biopsy of the pancreatic mass.\n* Measurable or non-measurable but evaluable (as determined by Response Evaluation Criteria in Solid Tumors version 1.1 \\[RECIST 1.1\\]) resectable, borderline resectable or unresectable locally advanced PDAC.\n* Subject has adequate performance status as defined by ECOG performance status 0 or 1.\n* Subject has received no prior chemotherapy or chemoradiotherapy for pancreatic cancer. Subjects have not previously received surgery to remove pancreatic cancer.\n* Age ≥ 18 years of age.\n* Subject has adequate organ function at study entry.\n* Subject has life expectancy of at least 6 months.\n\nExclusion Criteria:\n\n* Subject has any evidence of local recurrence or metastatic pancreatic cancer.\n* Other malignancies within the past 5 years except for adequately treated cervical or vulvar carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (Ta, Tis and T1).\n* Subject has hypersensitivity to 5FU, oxaliplatin or other platinum agent, or irinotecan or to their excipients.\n* Subject has known dihydropyrimidine dehydrogenase (DPD) enzyme deficiency.\n* Participation in any investigational drug study within 4 weeks preceding the start of study treatment. Subjects are not permitted to participate in another investigational drug study while being treated on this protocol. Subjects participating in other clinical trials that are receiving SOC FOLFIRINOX are permitted on study.\n* Subject has current evidence of any condition that makes participating in this study not in the best interest of the subject, including but not limited to:\n\n  * Myocardial infarction within the past 6 months\n  * New York Heart Association (NYHA) Class III or IV heart disease\n  * Active infection requiring IV antibiotics\n* Subject has a history of or suspected Gilbert's syndrome or known homozygosity for UGT1A1\\*28 polymorphism (baseline testing not required).\n* Subject has sensory peripheral neuropathy grade ≥ 2.\n* Major surgery, open biopsy or significant traumatic injury within 4 weeks of first study drug.\n* Subject is unable or unwilling to discontinue use of ketoconazole or St John's wort. Use of phenytoin, carbamazepine, phenobarbital, rifampin and rifabutin is discouraged, but not contraindicated. If subjects require phenytoin, carbamazepine or phenobarbital monitoring of drug levels is suggested during the study.\n* Subject is pregnant or lactating.\n* Psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the subject before registration in the trial.","99 Years",{"count":105,"type":20},45,[24],"This is a research study to evaluate how the genetic makeup of Pancreatic Ductal Adenocarcinoma (PDAC) can affect the response to FDA-approved chemotherapy treatment, FOLFIRINOX, given before surgery to remove the tumor. Certain types of PDAC tumors can be surgically resected (removed). However, not all types of PDACs are resectable, especially if they are close to important structures like blood vessels or intestines. These types of PDACs are treated with chemotherapy such as FOLFIRINOX. Research studies showed that chemotherapy after surgical resection of PDAC tumors reduced the risk of the cancer returning.\n\nChemotherapy is used to treat PDAC that has not spread outside of the pancreas and is not resectable. FOLFIRINOX is a chemotherapy treatment that combines multiple chemotherapeutic agents, including oxaliplatin, leucovorin, irinotecan, and 5-FU. Patients receive these agents by intravenous infusion. Of these drugs, 5-FU requires you to return home with a chemotherapy pump that will deliver chemotherapy over 46 hours. This regimen has been studied in pancreatic cancer that has been removed with surgery as a method for preventing the cancer from returning. Studies showed FOLFIRINOX chemotherapy reduced the risk of cancer returning and increased patients survival. In this study, researchers want to know if FOLFIRINOX chemotherapy given before surgery will make the cancer easier to remove with surgery and increase the chances of the cancer staying away after surgery.\n\nResearchers have shown that pancreatic cancers are not all the same when you look at the DNA and RNA that is inside a pancreatic cancer cell.\n\nDepending on the expression of different genes in a cancer cell, some pancreatic cancers may respond differently to chemotherapy. In this study researchers want to know if FOLFIRINOX chemotherapy can change the genetic profile of the cancer. This will be studied by obtaining a biopsy of the cancer before the start of chemotherapy, and after 8 treatments of chemotherapy. They will also study cancer cells that will be collected from blood samples.",[109,110,111,112,113,27,114],"Pancreatic Ductal Adenocarcinoma (PDAC)","Cancer of Pancreas","Pancreatic Cancer, Adult","Pancreas Adenocarcinoma","Pancreatic Neoplasms","Pancreatic Cancer Resectable",[116,27,114,117,118,111],"Pancreatic Ductal Adenocarcinoma","neoadjuvant FOLFIRNOX","FOLFIRINOX","2026-01-09",{"date":121,"type":32},"2026-01-13",{"date":123,"type":32},"2019-06-12",{"date":125,"type":20},"2030-01",{"name":127,"class":68},"UNC Lineberger Comprehensive Cancer Center",{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":136,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":139,"phases":4,"briefSummary":140,"conditions":141,"keywords":150,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":165},"100545979","pancreatic-cancer-detection-consortium-100545979","NCT06388967","Pancreatic Cancer Detection Consortium","Early Detection of Pancreatic Cancer: Prospective Study","PCDC","Inclusion Criteria:\n\n* Histological diagnosis of pancreatic ductal adenocarcinoma, stages I-IV (TNM classification, 8th edition)\n* Received standard diagnostic and staging procedures as per local guidelines, and at least one sample was drawn before receiving any curative-intent treatment.\n* Imaging- or endoscopy-based proof of lack of pancreatic ductal adenocarcinoma at the time of sampling (Non-disease controls)\n\nExclusion Criteria:\n\n* Lack of written informed consent.",true,{"count":138,"type":20},2000,"OBSERVATIONAL","This study aims to prospective validate an exosome-based miRNA signature for noninvasive and early detection of pancreatic ductal adenocarcinoma.",[142,143,144,116,113,145,146,114,147,148,149,111,27],"Pancreatic Cancer","Pancreatic Carcinoma","Pancreatic Adenocarcinoma","Pancreatic Cancer Stage I","Pancreatic Cancer Stage","Pancreatic Cancer Stage 0","Pancreatic Cancer Stage II","Pancreatic Cancer Stage III",[151,152,153,154,155],"Micro RNA","Exosome","Cell free","Early detection","Screening","2025-12-17",{"date":158,"type":32},"2025-12-19",{"date":160,"type":32},"2023-03-15",{"date":162,"type":20},"2026-06-18",{"name":164,"class":68},"City of Hope Medical Center",11,{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":21,"phases":175,"briefSummary":177,"conditions":178,"keywords":179,"overallStatus":185,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":4},"100616225","phase-4-tunlametinib--ag--cetuximab--as-first-line-therapy-for-advanced-pancreatic-cancer-100616225","NCT07302841","Tunlametinib + AG + Cetuximab β as First-Line Therapy for Advanced Pancreatic Cancer","A Clinical Study Evaluating the Efficacy and Safety of Tunlametinib in Combination With Chemotherapy and Cetuximab β in Patients With Advanced Pancreatic Cancer","Inclusion Criteria:\n\n1. Signing of a written informed consent form prior to enrolment;\n2. Age \\> 18 years, males and females eligible;\n3. Patients with histologically or pathologically confirmed advanced pancreatic cancer;\n4. No prior systemic therapy;\n5. At least one measurable lesion according to RECIST v1.1 assessment;\n6. ECOG Performance Status: 0-1;\n7. Expected survival greater than 12 weeks;\n8. Major organ function meeting the following requirements:\n\n   * Haemogram: Neutrophils ≥ 1.5 × 10⁹\u002FL; Platelet count ≥ 100 × 10⁹\u002FL; Haemoglobin ≥ 90 g\u002FL; Maintenance of these haematological parameters without G-CSF, platelet transfusion, TPO infusion, blood transfusion, or erythropoietin support for 14 days prior to first dose.\n   * Hepatic and Renal Function: Serum creatinine (SCr) ≤ 1.5 times the upper limit of normal (ULN) or creatinine clearance ≥ 50 ml\u002Fmin (Cockcroft-Gault formula); Total bilirubin (TBIL) ≤ 3 times the upper limit of normal (ULN); Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels ≤ 5 times ULN; Urine protein \\\u003C2+; if urine protein ≥2+, 24-hour urine protein quantification must show protein ≤1g;\n   * Creatine kinase (CK) ≤ 1.5 × ULN\n9. Normal coagulation function with no active bleeding or thrombotic disorders: International Normalised Ratio (INR) ≤ 1.5 × ULN; Activated Partial Thromboplastin Time (APTT) ≤ 1.5 × ULN; Prothrombin Time (PT) ≤ 1.5 × ULN;\n10. Non-surgically sterilised or female patients of childbearing potential must use one medically approved contraceptive method (e.g., intrauterine device, oral contraceptive, condom) during study treatment and for 3 months post-treatment. Non-surgically sterilised female patients of childbearing potential must have negative serum or urinary hCG tests within 7 days prior to study entry and must not be lactating. Male subjects who are not surgically sterilised or who are of reproductive age must agree to use one medically approved contraceptive method with their partner during the study treatment period and for 3 months after the study treatment period.\n11. Able to take oral medication;\n12. The subject voluntarily participates in this study, demonstrates good compliance, and cooperates with safety and survival follow-up.\n\nExclusion Criteria:\n\n1. Known contraindications affecting the investigator's choice of therapeutic agent (as per the latest prescribing information)\n2. Receipt of any other investigational treatment within 4 weeks prior to study dosing initiation;\n3. Undergoing major surgery (excluding biopsy, minor outpatient procedures such as vascular access placement) or experiencing severe trauma within 4 weeks prior to first dosing, or having scheduled major surgery within 30 days after first dosing (as determined by the investigator);\n4. Previous receipt of anti-EGFR monoclonal antibodies, EGFR tyrosine kinase inhibitors, or other EGFR-targeted therapies (e.g., cetuximab, nintedanib, panitumumab);\n5. Presence of clinically symptomatic third-space effusions uncontrollable by drainage or other methods (e.g., massive pleural effusion or ascites);\n6. Symptomatic or untreated brain metastases, leptomeningeal metastases, or spinal cord compression, except for asymptomatic brain metastases (i.e., no progressive CNS symptoms attributable to brain lesions, no requirement for corticosteroids or antiepileptic drugs, and imaging confirmation of stable disease for ≥4 weeks); Patients undergoing stereotactic brain radiotherapy or surgery may be eligible if no disease progression is observed in the brain over a period of ≥3 months;\n7. Cardiac impairment or clinically significant cardiovascular disease with uncontrolled cardiac symptoms or conditions, such as: (1) NYHA Class II or higher heart failure; (2) unstable angina pectoris; (3) myocardial infarction within the past year; (4) clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention;\n8. History or presence at screening of retinal disease, including: retinal vein occlusion (RVO), retinal artery occlusion, retinal vasculitis, diabetic retinopathy, hypertensive retinopathy, retinal capillaropathy (Costs disease), retinal pigment epithelial detachment (RPED); Presence of RVO risk factors at screening (e.g., uncontrolled glaucoma or ocular hypertension, history of hyperviscosity or hypercoagulable syndromes); retinal diseases such as RPED;\n9. Patients with interstitial lung disease or interstitial pneumonia, including clinically significant radiation pneumonitis (i.e., affecting activities of daily living or requiring intervention);\n10. Known active pulmonary tuberculosis (TB); subjects suspected of active TB must undergo clinical evaluation to rule it out; known active syphilis infection;\n11. Human immunodeficiency virus (HIV) antibody positive, syphilis antibody (Anti-TP) positive, hepatitis C virus (HCV) antibody positive with HCV RNA positive, hepatitis B virus surface antigen (HBsAg) positive with HBV DNA positive (HBsAg positive requires further testing for HBV DNA, HBV DNA ≥ 200 IU\u002Fml, or ≥ 10³ copies\u002Fml);\n12. History of chronic inflammatory bowel disease or Crohn's disease requiring medical intervention (immunomodulators or surgery) within 12 months prior to treatment initiation;\n13. Known history of acute or chronic pancreatitis within 6 months prior to study treatment initiation;\n14. History of allogeneic bone marrow transplantation or organ transplantation;\n15. Uncontrolled active infectious disease requiring intravenous antibiotics, antifungals, or antivirals within 2 weeks prior to first dosing, or unexplained fever \\>38.5°C during screening\u002Fprior to first dosing;\n16. Uncorrectable electrolyte abnormalities (hypokalaemia, hypomagnesaemia, hypocalcaemia confirmed by blood biochemistry);\n17. Past or current neuromuscular disorders associated with elevated CK levels (e.g., inflammatory myopathies, muscular dystrophies, amyotrophic lateral sclerosis, spinal muscular atrophy, rhabdomyolysis syndrome);\n18. Arterial or venous thromboembolic events occurring within 6 months prior to first administration, such as cerebrovascular accidents (including transient ischaemic attacks, cerebral haemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary embolism;\n19. Presence of oesophageal or gastric varices, severe ulcers, unhealed wounds, gastrointestinal perforation, abdominal fistula, intra-abdominal abscess, or history of acute gastrointestinal haemorrhage within 6 months prior to first administration; occurrence of hypertensive crisis or hypertensive encephalopathy within 6 months prior to first administration; acute exacerbation of chronic obstructive pulmonary disease within 1 month prior to first administration;\n20. Grade 3 bleeding events as defined by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v5.0) within 4 weeks prior to first dosing;\n21. History of severe bleeding tendency or coagulation disorders; screening imaging demonstrating tumour encasement of major vessels or significant necrosis\u002Fcavitation, where the investigator deems participation may pose a bleeding risk;\n22. Current radiographic or clinical evidence of significant gastrointestinal obstruction;\n23. History of other malignancies within the past 5 years, except for patients with completely cured basal cell carcinoma or squamous cell carcinoma of the skin, cervical carcinoma in situ, and\u002For any malignancy that has been cured with no evidence of disease or at least 5 years of continuous disease-free status;\n24. Known allergy to any component of the study drug;\n25. History of defined neurological or psychiatric disorders, including epilepsy and dementia;\n26. Failure of all relevant antineoplastic treatment toxicities to recover to Grade ≤1 (as assessed per NCI CTCAE V5.0) prior to study drug administration;\n27. Concurrent use of other antineoplastic agents for concomitant therapy (bisphosphonates for bone metastases are acceptable);\n28. Uncontrolled concomitant conditions, including but not limited to severe diabetes mellitus (fasting blood glucose \\> 250 mg\u002Fdl or 13.9 mmol\u002FL) or other serious illnesses requiring systemic treatment;\n29. Recipient of live or attenuated vaccines within 4 weeks prior to first dosing (Note: If enrolled, subjects must not receive live vaccines during study treatment or within 30 days after the last study drug dose);\n30. Positive pregnancy test results in premenopausal female subjects (postmenopausal female subjects must have been amenorrheic for at least 12 months to be considered non-fertile); subjects of reproductive age (including female partners of male subjects) who are likely to become pregnant, are breastfeeding, or are unwilling to use effective contraception during the study period and for at least 30 days after the last dose of study medication;\n31. Patients currently receiving intravenous or oral medications that are prohibited by the protocol due to their effects on CYP isoenzymes (strong inducers or inhibitors of CYP2C9 and CYP3A4) and cannot be discontinued at least one week prior to study treatment initiation and throughout the study period; patients taking narrow therapeutic index medications metabolised via CYP1A2;\n32. Inability to swallow capsules, or refractory nausea and vomiting, malabsorption, extrahepatic bile diversion, or significant small bowel resection that may impair adequate absorption of the study drug;\n33. Other circumstances deemed unsuitable for inclusion by the investigator. For example, family or social factors that may compromise the subject's safety or the collection of data and samples.",{"count":174,"type":20},28,[176],"PHASE4","This study is a prospective, open-label, single-arm clinical trial evaluating the safety and efficacy of tunlametinib in combination with gemcitabine\u002Falbumin-bound paclitaxel and an EGFR monoclonal antibody as first-line therapy in treatment-naive subjects with advanced pancreatic cancer.",[27],[180,181,182,183,184],"first-line therapy in treatment","MEK inhibitor","AG","Tunlametinib","Cetuximab β","NOT_YET_RECRUITING","2025-12-11",{"date":188,"type":32},"2025-12-24",{"date":190,"type":20},"2026-01-20",{"date":192,"type":20},"2028-12-30",{"name":194,"class":68},"Tianjin Medical University Cancer Institute and Hospital",{"id":196,"slug":197,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":201,"eligibilityCriteria":202,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":203,"targetDuration":4,"studyType":21,"phases":205,"briefSummary":206,"conditions":207,"keywords":210,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":40},"100562612","phase-2-medical-cannabis-in-patients-with-advanced-pancreatic-and-colorectal-cancer-100562612","NCT06605430","Medical Cannabis in Patients With Advanced Pancreatic and Colorectal Cancer","A Randomized Phase II Trial of Medical Cannabis to Reduce Symptom Burden in Patients With Advanced Pancreatic and Colorectal Cancer (CanPan-C)","CanPan-C","Inclusion Criteria\n\n1. Adults (aged 18 or more at enrollment)\n2. Histologically or cytologically proven pancreatic or colorectal cancer. Histologies may include listing of adenocarcinoma, poorly differentiated carcinoma, or other pathology terms that treating oncologist would consider managing per usual standard of care of pancreas and colorectal adenocarcinoma. Neuroendocrine tumors are excluded in both cancer types.\n3. Advanced stage (locally advanced or metastatic) pancreatic or colorectal cancer with no definitive plans for curative surgery in the next 3 months\n4. Self-report of experiencing nausea, vomiting, anorexia, cachexia (wasting), or pain at least once in the 14 days prior to randomization\n5. Plan to initiate or initiated within the past 2 weeks standard-of-care systemic chemotherapy (any regimen that does not include immunotherapy) at a participating institution with no prior systemic therapy in the prior 3 months (prior adjuvant or neoadjuvant chemotherapy is allowed as long as it was \\>3 months prior to randomization)\n6. Must be a resident of Minnesota\n7. Must be willing to be registered in the Minnesota Medical Cannabis Program and follow all rules and requirements of the state program\n8. Must be willing to report baseline and required patient-reported outcomes\n\nExclusion Criteria\n\n1. Self-reported regular use (using 10 or more days in the 30 days prior to randomization) of a THC containing cannabinoid product\n2. Patients with a history of intolerance or hypersensitivity to cannabis (i.e., cannabis hyperemesis)\n3. Patients with Alzheimer's dementia, active epilepsy, or history of traumatic brain injury\n4. Patients with known active or untreated brain metastases. A brain MRI is not required during the screening period.\n5. Patients initiating or receiving immunotherapy, a chemotherapy-immunotherapy combination, or non-standard cytotoxic chemotherapy (including patients enrolled\u002F enrolling in trials of investigational cancer-directed treatments)\n6. Women who are pregnant, breastfeeding or of childbearing potential without the use of birth control\n7. Uncontrolled acute or chronic medical conditions, psychiatric conditions or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for enrollment in this study\n8. Has any condition that in the opinion of the investigator might jeopardize the safety of the subject or interfere with protocol compliance",{"count":204,"type":20},64,[24],"Many patients with advanced pancreatic cancer and colorectal cancer experience burdensome and difficult-to-treat symptoms. The impact of multiple symptoms (called \"symptom burden\") can negatively affect a patient's quality of life, decrease their ability to tolerate cancer treatments, and lead to worse survival. Current approaches to manage these cancer-associated symptoms often work poorly, with most patients reporting a moderate to severe symptom burden. Therefore, there is an urgent need for treatments that improve these symptoms in patients with advanced pancreatic and colorectal cancer, and data suggests that medical cannabis can help. In this research study, we are examining the usefulness of using medical cannabis in patients with advanced pancreatic cancer and colorectal cancer to further study how cannabis can impact their symptom burden.",[27,208,209],"Pancreatic Cancer Metastatic","Colorectal Cancer Metastatic",[211,212],"medical cannabis","patient-reported outcomes","2025-07-25",{"date":215,"type":32},"2025-07-29",{"date":217,"type":32},"2024-09-16",{"date":219,"type":20},"2026-12",{"name":221,"class":68},"HealthPartners Institute",{"id":223,"slug":224,"hasResults":11,"nctId":225,"briefTitle":226,"officialTitle":227,"acronym":228,"eligibilityCriteria":229,"healthyVolunteers":11,"sex":16,"minAge":230,"maxAge":231,"enrollmentInfo":232,"targetDuration":4,"studyType":21,"phases":234,"briefSummary":235,"conditions":236,"keywords":238,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":40},"100598092","phase-1-mesothelin-and-claudin-182-dual-target-car-t-therapy-in-advanced-pancreatic-cancer-100598092","NCT07066995","Mesothelin and Claudin 18.2 Dual-Target CAR-T Therapy in Advanced Pancreatic Cancer","Dual-Target Chimeric Antigen Receptor (CAR) T-Cell Therapy Directed Against Mesothelin and Claudin 18.2 in Patients With Advanced or Metastatic Pancreatic Cancer","BAH2573-102","Inclusion Criteria:\n\n* Expected survival time ≥3 months;\n* Histologically or cytologically confirmed pancreatic adenocarcinoma that is advanced (unresectable or metastatic). Patients should have received, or be intolerant of, standard first-line therapy (e.g., gemcitabine\u002Fnab-paclitaxel, FOLFIRINOX) for advanced disease. A short course of current first-line therapy is allowed for the purpose of bridging to manufacturing, but evidence of disease progression on or after at least one line is required prior to infusion (for the dose-expansion phase, patients must have progressed on ≥1 prior systemic regimen).\n* ECOG Performance Status: 0 or 1 (fully active or restricted in strenuous activity but ambulatory).\n* Liver and kidney function, cardiopulmonary function meet the following requirements:\n* Creatinine ≤1.5×ULN; (2) Electrocardiogram showed no clinically significant abnormal bands;\n* Blood oxygen saturation \\>91% in non-oxygen state;\n* Total bilirubin ≤2×ULN; ALT and AST≤2.5 x ULN; ALT and AST abnormalities due to disease, such as liver infiltration or bile duct obstruction, were determined to be less than 5×ULN. If Gilbert syndrome is diagnosed, the total bilirubin index can be relaxed to ≤3.0×ULN and the direct bilirubin ≤1.5×ULN.\n* No serious mental disorders;\n* Can understand this test and has signed the informed consent.\n\nExclusion Criteria:\n\n* Hepatitis B surface antigen (HBsAg) positive; Hepatitis B core antibody (HBcAb) positive and peripheral blood hepatitis B virus (HBV) DNA titer detection is not within the normal reference value range; Hepatitis C virus (HCV) Antibody positive and peripheral blood hepatitis C virus (HCV) RNA positive; Human immunodeficiency virus (HIV) Antibody positive; Syphilis positive;\n* Serious heart disease, including but not limited to unstable angina, myocardial infarction or bypass or stent surgery (within 6 months prior to screening), congestive heart failure (NYHA classification ≥III), and severe arrhythmia;\n* Systemic diseases that are deemed unstable by researchers: including but not limited to severe liver, kidney, or metabolic diseases that require drug treatment;\n* Active or uncontrollable infections (except mild genitourinary and upper respiratory tract infections) that require systemic treatment within 7 days prior to administration;\n* Pregnant or lactating women, and female subjects who plan pregnancy within 2 years after cell transfusion or male subjects whose partners plan pregnancy within 2 years after cell transfusion;\n* Patients who received CAR-T therapy or other gene-modified cell therapy before screening;\n* Participated in other clinical studies 1 month before screening;\n* Evidence of central nervous system invasion during subject screening;\n* Mental patients with depression or suicidal thoughts;\n* Situations considered unsuitable for inclusion by other researchers.","21 Years","90 Years",{"count":233,"type":20},60,[23,24],"Autologous T-cells engineered to express CARs targeting Mesothelin and Claudin18.2, for Unresectable locally advanced or metastatic pancreatic adenocarcinoma (Pancreatic Ductal Adenocarcinoma, PDAC), administered as two separate sequential infusions following lymphodepleting chemotherapy",[142,143,27,237],"Pancreatic Cancer Stage IV",[142,239,143,240,241],"claudin 18.2","CAR-T","Mesothelin","2025-07-04",{"date":244,"type":32},"2025-07-15",{"date":246,"type":32},"2025-04-29",{"date":248,"type":20},"2028-12-28",{"name":250,"class":68},"Essen Biotech",{"id":252,"slug":253,"hasResults":11,"nctId":254,"briefTitle":255,"officialTitle":256,"acronym":4,"eligibilityCriteria":257,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":258,"targetDuration":4,"studyType":139,"phases":4,"briefSummary":260,"conditions":261,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":40},"100588176","outcomes-of-ablation-of-unresectable-pancreatic-cancer-using-the-nanoknife-irreversible-electroporation-system--100588176","NCT06937996","Outcomes of Ablation of Unresectable Pancreatic Cancer Using the NanoKnife Irreversible Electroporation System-","Outcomes of Ablation of Unresectable Pancreatic Cancer Using the NanoKnife Irreversible Electroporation (IRE) System","Inclusion Criteria:\n\n* \\> = 18 years of age\n* Must be found to have locally advanced unresectable disease following standard chemotherapy ± radiotherapy as demonstrated with either CT\u002FMRI imaging and surgical evaluation, and not have taken any chemotherapy\u002Fradiotherapy within 5 weeks of treatment with the NanoKnife IRE System\n* Must have an INR \\\u003C 1.5\n* Are willing and able to comply with the protocol requirements\n* Are able to comprehend and willing to sign an informed consent form\n\nExclusion Criteria:\n\n* Creatinine \\> 2.0 mg\u002FdL\n* Any lab value with a grade 3 or 4 toxicity as defined by the CTCAE Version 5.0\n* Inability to stop antiplatelet and coumadin therapy for 7 days prior to and 7 days post treatment with the NanoKnife System\n* Tumor size not measurable\n* Known history of contrast allergy that cannot be medically managed\n* Known hypersensitivity to the metal in the electrodes (stainless steel 304L) that cannot be medically managed\n* Unable to be treated with a muscle blockade agent (e.g. pancuronium bromide, atracurium, cisatracurium, etc.)\n* Women who are pregnant or currently breast feeding\n* Women of childbearing potential who are not utilizing an acceptable method of contraception\n* Have taken an investigational agent within 30 days of visit 1\n* Have implanted cardiac pacemakers or defibrillators\n* Have implanted electronic devices or implants with metal parts in the vicinity of a lesion\n* Have a history of epilepsy or cardiac arrhythmia (atrial or ventricular fibrillation)\n* Have a recent history of myocardial infarction (within the past 2 months)\n* Have Q-T intervals greater than 550 ms unless treated with an Accysync Model 72 synchronization system controlling the NanoKnife system's output pulses\n* Evidence of distant metastases of stage IV\n* Have taken any chemotherapeutic agent within 5 weeks of treatment with the NanoKnife Irreversible Electroporation (IRE) System\n* Received non-conventional fractionation schedules, such as stereotactic radiation (5 fractions or less) or received higher than 54 Gray (Gy) delivered conventionally",{"count":259,"type":20},25,"The purpose of this study is to evaluate the short and intermediate term safety of the NanoKnife Irreversible Electroporation System when used off-label to treat unresectable pancreatic cancer. In addition, the study will evaluate the efficacy of this device in treating pain associated with unresectable pancreatic cancer. Quality of life post-procedure will also be collected.",[27],"2025-06-12",{"date":264,"type":32},"2025-06-17",{"date":266,"type":32},"2025-05-13",{"date":268,"type":20},"2035-05-31",{"name":270,"class":68},"Englewood Hospital and Medical Center",{"id":272,"slug":273,"hasResults":11,"nctId":274,"briefTitle":275,"officialTitle":276,"acronym":277,"eligibilityCriteria":278,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":279,"enrollmentInfo":280,"targetDuration":4,"studyType":21,"phases":282,"briefSummary":283,"conditions":284,"keywords":285,"overallStatus":185,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":288,"startDateStruct":290,"completionDateStruct":292,"leadSponsor":294,"locationsCount":40},"100586561","phase-2-adebrelimab-combined-with-ag-regimen-in-patients-with-unresectable-locally-advanced-or-metastatic-pancreatic-cancer-100586561","NCT06916975","Adebrelimab Combined With AG Regimen in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer","A Prospective, Single-Arm, Phase II Clinical Trial of Adebrelimab Combined With AG Regimen in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer","CSPAC-48","Inclusion Criteria:\n\n* Sign informed consent；\n* Aged 18-75 years (inclusive)；\n* Histologically or cytologically confirmed pancreatic cancer；\n* Unresectable locally advanced or metastatic pancreatic cancer, as determined by the investigator；\n* Disease progression after prior treatment with at least one systemic therapy;\n* No previous immunotherapy;\n* No previous gemcitabine-based chemotherapy;\n* Have at least one measurable lesion (according to RECIST 1.1 criteria);\n* ECOG 0\\~1；\n* The estimated survival time is greater than 3 months;\n* Adequate Organ Function (within 28 days prior to first dose): Hematology: White blood cell count (WBC) ≥3.0×10⁹\u002FL Absolute neutrophil count (ANC) ≥1.5×10⁹\u002FL Platelets (PLT) ≥100×10⁹\u002FL Hemoglobin (HGB) ≥90 g\u002FL Liver Function: Aspartate aminotransferase (AST) ≤2.5×ULN Alanine aminotransferase (ALT) ≤2.5×ULN Total bilirubin (TBIL) ≤1.5×ULN Renal Function: Serum creatinine (Cr) ≤1.5×ULN or creatinine clearance (CrCl) ≥60 mL\u002Fmin (calculated via Cockcroft-Gault formula). Coagulation: International normalized ratio (INR) ≤1.5 Activated partial thromboplastin time (APTT) ≤1.5×ULN Cardiac Function: No clinically significant abnormalities on electrocardiogram (ECG)；\n* Male subjects and females of childbearing potential must agree to use effective contraceptive measures from the first dose until 3 months after the last dose of the study drug.\n\nExclusion Criteria:\n\n* The subject has any known active autoimmune disease;\n* Subjects have any complications requiring systemic treatment with corticosteroids such as prednisone (\\> 10mg\u002F day) or have used immunosuppressive drugs within 14 days prior to initial administration;\n* Subjects received tumor vaccines or other immune-activating antitumor drugs (such as interferon, interleukin, thymosin, or immune cell therapy) within 1 month prior to initial administration;\n* Subjects are participating in another clinical trial or have received a drug intervention from another clinical trial within 4 weeks prior to the first dose;\n* Subjects have other malignancies requiring treatment;\n* Clinically significant cardiovascular disorders；\n* Prior allogeneic organ transplantation or hematopoietic stem cell transplantation；\n* Serologically confirmed HIV infection；\n* Active hepatitis B (HBsAg-positive with HBV-DNA ≥10³ copies\u002FmL). Active hepatitis C (HCV antibody-positive with detectable HCV RNA and requiring antiviral therapy)；\n* Known hypersensitivity to monoclonal antibodies or any component of adebrelimab；\n* History of severe allergic reactions to gemcitabine or nab-paclitaxel；\n* Any situation that the investigator believes may compromise the validity of the trial or patient safety.","75 Years",{"count":281,"type":20},46,[24],"This study aims to evaluate the efficacy and safety of adebrelimab combined with the AG regimen in patients with unresectable locally advanced or metastatic pancreatic cancer who have received at least one prior line of systemic therapy but have not undergone gemcitabine-based treatment.",[27,208],[286],"pancreatic cancer","2025-04-01",{"date":289,"type":32},"2025-04-08",{"date":291,"type":20},"2025-04-15",{"date":293,"type":20},"2028-12-01",{"name":295,"class":68},"Jin Xu",{"id":297,"slug":298,"hasResults":11,"nctId":299,"briefTitle":300,"officialTitle":301,"acronym":4,"eligibilityCriteria":302,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":303,"enrollmentInfo":304,"targetDuration":4,"studyType":21,"phases":306,"briefSummary":307,"conditions":308,"keywords":309,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":314,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":40},"100580651","clinical-study-of-carbon-ion-radiotherapy-for-pancreatic-cancer-100580651","NCT06840067","Clinical Study of Carbon Ion Radiotherapy for Pancreatic Cancer.","Single-arm Clinical Study of Carbon Ion Radiotherapy Combined with Nituzumab and Gemcitabine for Pancreatic Cancer.","Inclusion Criteria:\n\n1. Age ≥18 years and ≤80 years;\n2. Indications: patients with locally advanced or metastatic pancreatic adenocarcinoma confirmed by histopathology or cytology (stage III - IV).\n3. At least one measurable lesion was present according to RECIST version 1.1 evaluation criteria.\n4. Suitable for one cycle of gemcitabine combined with nituzumab.\n5. No history of other malignant tumors (except cured skin cancer and stage 0 cervical cancer);\n6. Liver function, kidney function and bone marrow function were basically normal (ALT and AST \\\u003C 1.5 times of high normal value (ULN), bilirubin \\\u003C 1.5×ULN; Adult endogenous creatinine clearance rate of 60ml\u002Fmin or serum creatinine SCR≤140μmoI\u002FL, BUN≤6.8mmol\u002FL; Hemoglobin level \\>9 g\u002FdL; White blood cell count ≥3.0\\*109\u002FL; Platelet count ≥100\\*109\u002FL;)\n7. Good physical condition, i.e. ECOG (Eastern United States Oncology Collaboration Group) 0\\~2; There were no complications such as severe pulmonary hypertension, cardiovascular disease, peripheral vascular disease, and severe chronic heart disease that may affect radiotherapy. Cardiac function grade 1. (According to the New York College of Cardiology Cardiac Function Scale (NYHA)\n8. Adequate functions of major organs;\n9. Predicted survival (after treatment) ≥3 months;\n10. Informed consent has been signed by the patient or his legal representative before radiotherapy.\n\nExclusion Criteria:\n\n1. Patients who have received monoclonal antibodies, EGFR-TKI therapy, anti-angiogenic drugs, and immunosuppressants within six months.\n2. Patients with uncontrolled, cancerous pleural effusion requiring frequent drainage, pericardial effusion, or ascites (allowing for cytological confirmation of effusion), gastrointestinal bleeding, or those identified by the investigator as having a high blood risk within 14 days prior to admission.\n3. Participated in other interventional clinical trials within 30 days prior to screening.\n4. The dose limit for organs at risk cannot reach the preset safe dose limit.\n5. Being on chronic steroid hormone therapy for more than 6 months (e.g., prednisone dose \\> 10 mg\u002F day or equivalent).\n6. People who are allergic to the drugs or their ingredients used in this program.\n7. Pregnancy (confirmed by serum or urine β-HCG test) or lactation\n8. Persons with AIDS, including those who have received antiretroviral therapy; Active stage of syphilis;\n9. Accompanied by serious comorbiditions, including uncontrolled systemic or co-existing diseases (pulmonary insufficiency, cardiovascular, pulmonary, liver, kidney, diabetes, etc.), drug or alcohol abuse, dependence, addiction, and\u002For mental illness that prevent the successful implementation of the trial protocol;\n10. Patients with poor compliance, including those who may not be able to complete the treatment plan or receive prescribed follow-up and examination;\n11. Patients had other malignant neoplasms (except cured skin cancer and stage 0 cervical cancer);\n12. There are contraindications to radiotherapy;\n13. having no or limited capacity for civil conduct;\n14. Any medical history that, in the investigator's judgment, might interfere with the trial results or increase the patient's risk;\n15. Any condition in which the physician considers that participation in the trial is not appropriate, the physician determines that the patient will not benefit from carbon ion radiotherapy, or that there are other co-existing conditions or other factors that may affect carbon ion therapy.\n16. Inability to understand the purpose of treatment or unwillingness\u002Finability to sign treatment consent.","80 Years",{"count":305,"type":20},62,[79],"The objective is to evaluate the efficacy and safety of carbon ion radiotherapy (CIRT) combined with nituzumab and gemcitabine in the treatment of locally advanced and metastatic pancreatic cancer.",[208,27],[310,286,311,312],"Carbon Ion Radiotheray","Nimotuzumab","Gemcitabine","2025-03-22",{"date":315,"type":32},"2025-03-25",{"date":317,"type":32},"2025-03-01",{"date":319,"type":20},"2028-12-31",{"name":321,"class":68},"Gansu Wuwei Tumor Hospital",{"id":323,"slug":324,"hasResults":11,"nctId":325,"briefTitle":326,"officialTitle":327,"acronym":4,"eligibilityCriteria":328,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":279,"enrollmentInfo":329,"targetDuration":4,"studyType":21,"phases":331,"briefSummary":332,"conditions":333,"keywords":4,"overallStatus":185,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":335,"startDateStruct":337,"completionDateStruct":338,"leadSponsor":340,"locationsCount":40},"100584385","phase-1-personalized-tumor-neoantigen-mrna-therapy-for-advanced-pancreatic-cancer-100584385","NCT06888648","Personalized Tumor Neoantigen MRNA Therapy for Advanced Pancreatic Cancer.","Clinical Study to Evaluate the Safety and Efficacy of Personalized Tumor Neoantigen MRNA Therapy in Combination with PD-1 Antibody and Chemotherapy for Advanced Pancreatic Cancer.","Inclusion Criteria:\n\n(1) Subjects who meet all the following entry criteria enter the pre-screening phase of the study:\n\n1. Voluntary signing of the informed consent form;\n2. Age: 18 and 75 years old, male or female;\n3. Evaluation as metastatic pancreatic cancer or postoperative recurrence according to the 2024 NCCN guidelines;\n4. No systemic treatment, or disease progression with gemcitabine-based first-line chemotherapy.\n5. An Eastern Cooperative Oncology Group (ECOG) physical fitness status score of 0 or 1;\n6. According to the efficacy evaluation criteria for solid tumors (RECIST 1.1);\n7. Can obtain sufficient fresh tumor tissue samples for exome and transcriptome sequencing analysis;\n8. Main organ function of heart, liver and kidney is normal:\n9. Ferproductive men and women of childbearing age agree to take effective contraception from the date to the last dose of test drug; women of childbearing age included premenopause and women within 2 years after menopause;\n10. Ability to follow the study protocol and follow-up procedures.\n\n(2) Subjects who meet all the following enrollment criteria enter the formal screening stage of the study and enter the study medication process:\n\n1. Voluntary signing of the informed consent form;\n2. Age: 18 and 75 years old, male or female;\n3. Pancreatic ductal adenocarcinoma (PDAC) diagnosed by pathology (histology or cytology);\n4. No systemic treatment or gemcitabine-based first-line chemotherapy.\n5. An Eastern Cooperative Oncology Group (ECOG) physical fitness status score of 0 or 1;\n6. Main organ function of heart, liver and kidney is normal:\n7. Ferproductive men and women of childbearing age agree to take effective contraception from the date to the last dose of test drug; women of childbearing age include premenopause and women within 2 years after menopause;\n8. Ability to follow the study protocol and follow-up procedures.\n\nExclusion Criteria:\n\nSubjects will be excluded from this study if they meet any of the following criteria:\n\n1. Pancreatic cancer has central nervous system metastasis or meningeal metastasis;\n2. At the same time with other malignant tumors, but cured basal cell cancer, thyroid cancer, cervical dysplasia, etc., have been in the disease for more than 5 years or do not considered to be easy to relapse except;\n3. History of bone marrow transplantation, allogeneic organ transplantation, or allogeneic hematopoietic stem cell transplantation;\n4. Patients with immunosuppressants, that is, those who require regular use of immunosuppressants 4 weeks before the screening period and the clinical study, including but not limited to the following conditions: severe asthma, autoimmune diseases or immune deficiency, treated with immunosuppressive drugs, and known history of primary immunodeficiency; except type 1 diabetes, autoimmune-related hypothyroidism requiring hormone therapy, vitiligo and psoriasis that do not require systemic therapy;\n5. Active bacterial or fungal infection identified by clinical diagnosis; a history of active TB or tuberculosis;\n6. Patients with positive human immunodeficiency virus (HIV) antibody, positive treponema pallidum for syphilis (TP) antibody, active hepatitis C (positive hepatitis C virus (HCV) antibody and positive HCV RNA result), active hepatitis B;\n7. Herpesvirus infection (except those who scab for more than 4 weeks); respiratory virus infection (except those who have recovered for more than 4 weeks);\n8. Uncontrolled complications include but are not limited to active infection, symptomatic congestive heart failure, unstable angina, arrhythmia; severe coronary artery disease or cerebrovascular disease, or other diseases considered unacceptable by the investigator;\n9. Previous history of drug abuse, clinical or psychological or social factors affecting informed consent or study implementation; a history of mental illness;\n10. Patients with a history of food, drug or vaccine allergy or other potential immunotherapy allergies as considered by the Investigator.\n11. Women born during pregnancy or lactation;\n12. The investigator is not fit for enrollment or may not complete the trial for other reasons.",{"count":330,"type":20},30,[23,24],"This study is a single-arm phase I\u002FII clinical study to evaluate the effectiveness of evaluate the feasibility and safety of personalized tumor neoantigen mRNA therapy (iNeo-Vac-R01) in combination with PD-1 antibody and standard chemotherapy regimens for the treatment of patients with advanced pancreatic cancer.",[208,27],"2025-03-15",{"date":336,"type":32},"2025-03-21",{"date":287,"type":20},{"date":339,"type":20},"2028-04-01",{"name":341,"class":68},"Zhejiang University",{"id":343,"slug":344,"hasResults":11,"nctId":345,"briefTitle":346,"officialTitle":347,"acronym":4,"eligibilityCriteria":348,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":279,"enrollmentInfo":349,"targetDuration":4,"studyType":21,"phases":350,"briefSummary":352,"conditions":353,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":355,"startDateStruct":357,"completionDateStruct":359,"leadSponsor":361,"locationsCount":40},"100554777","early-phase-1-a-trail-of-second-line-chemotherapy-sequential-nkg2d-car-nk-cell-therapy-for-pancreatic-cancer-100554777","NCT06503497","A Trail of Second-line Chemotherapy Sequential NKG2D CAR-NK Cell Therapy for Pancreatic Cancer","A Single-center, Single-arm, Open-label, Dose-escalation Clinical Study to Evaluate the Safety and Anti-tumor Efficacy of Second-line Systemic Chemotherapy Sequential NKG2D CAR-NK Cell Therapy for Pancreatic Cancer","Inclusion Criteria:\n\n* 1\\. Age between 18\\~75 years old (including boundary value), both male and female.\n* 2\\. Histologically or cytologically confirmed pancreatic ductal adenocarcinoma or IPMN carcinosis with at least first-line systemic therapy failure.\n* 3\\. Zubrod-ECOG-WHO score (see Annex 2) on a scale of 0-2.\n* 4\\. Life expectancy of at least 3 months at screening, as judged by the investigator.\n* 5\\. At least one stably evaluable target lesion according to RECIST1.1 criteria.\n* 6\\. Subject has adequate organ and bone marrow function. Laboratory screening results should be within the stable range described below, with no ongoing supportive care (\\"yellowing\\" therapy such as PTCD, ENBD, or bile duct stenting is allowed when pancreatic cancer invades the common bile duct).\n* 7\\. Remission of all toxicities due to prior antineoplastic therapy to Grade 0\\~1 (according to NCI CTCAE version 5.0) or to acceptable levels for inclusion\u002Fexclusion criteria.\n* 8\\. Childbearing status: not pregnant, and if of childbearing potential, willing to use effective contraception from the time of signing the informed consent form to 6 months after the last cell infusion (females of childbearing potential include premenopausal females and females within 2 years of postmenopause).\n* 9\\. Subjects must sign and date written informed consent.\n* 10\\. Subjects must be voluntary and able to comply with predetermined treatment regimens, laboratory tests, follow-up, and other study requirements.\n\nExclusion Criteria:\n\n* 1\\. Pregnant and lactating females.\n* 2\\. Positive serology for HIV, Treponema pallidum or HCV (those who are HCV antibody positive but HCV-RNA negative, stable syphilis and inactive patients can be included).\n* 3\\. Any active infection, including but not limited to active tuberculosis, HBV infection (including HBsAg positive, or HBcAb positive with HBV DNA above the lower limit of laboratory testing), Epstein-Barr virus (EBV) DNA positive, cytomegalovirus (CMV) DNA positive or novel coronavirus (new coronavirus) nucleic acid positive, and other bacterial, viral, or fungal infections requiring drug treatment;\n* 4\\. History of malignancy within 5 years, with the exception of basal cell carcinoma of the skin and carcinoma in situ of the cervix.\n* 5\\. Any other health condition that, in the judgment of the investigator, would preclude participation in the study.",{"count":330,"type":20},[351],"EARLY_PHASE1","This is a single-center, single-arm, open-label, dose-escalation clinical study to evaluate the safety and anti-tumor efficacy of second-line systemic chemotherapy sequential NKG2D CAR-NK cell therapy for pancreatic cancer",[27],"2024-12-21",{"date":356,"type":32},"2024-12-27",{"date":358,"type":32},"2024-07-09",{"date":360,"type":20},"2026-07-31",{"name":341,"class":68},{"id":363,"slug":364,"hasResults":11,"nctId":365,"briefTitle":366,"officialTitle":367,"acronym":4,"eligibilityCriteria":368,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":279,"enrollmentInfo":369,"targetDuration":4,"studyType":21,"phases":371,"briefSummary":372,"conditions":373,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":374,"startDateStruct":375,"completionDateStruct":377,"leadSponsor":379,"locationsCount":40},"100552851","early-phase-1-endoscopic-ultrasound-eus-intratumoral-injection-of-car-nk-cells-in-the-treatment-of-advanced-pancreatic-cancer-100552851","NCT06478459","Endoscopic Ultrasound (EUS) Intratumoral Injection of CAR-NK Cells in the Treatment of Advanced Pancreatic Cancer","A Single-center, Single-arm, Open-label, Dose-escalation Clinical Study to Evaluate the Safety and Anti-tumor Efficacy of Intratumoral NKG2D CAR-NK Cell Injection Guided by EUS in the Treatment of Locally Advanced Pancreatic Cancer.","Inclusion Criteria:\n\n1. 18\\~75 years old (including boundary value), both male and female.\n2. Histologically or cytologically confirmed pancreatic ductal adenocarcinoma or IPMN carcinogenesis.\n3. Recurrent or unresectable locally advanced pancreatic cancer. Patients with technically resectable tumors but are considered as unable to undergo surgical treatment due to medical comorbidities or the patient\\'s refusal of surgery are also eligible for enrollment.\n4. ECOG PS score of 0-1.\n5. At least 3 months of life expectancy at screening, as judged by the investigator.\n6. Subject has adequate organ and bone marrow function. Laboratory screening results should be within the stable range described below, and there should be no ongoing supportive care (\\"jaundice relieve\\" therapy such as PTCD, ENBD, or bile duct stenting is allowed when pancreatic cancer invades the common bile duct). a) Blood biochemistry: serum creatinine ≤ 1.5×ULN, serum total bilirubin ≤ 2.0×ULN, and serum liver aminotransferase ≤ 3 ×ULN b) Blood tests: neutrophil count ≥ 1.5×109\u002FL, platelet count ≥ 60×109\u002FL, hemoglobin ≥ 8.0g\u002FdL, lymphocyte count ≥ 0.4×109\u002FL;\n7. Childbearing status: not pregnant and, if of childbearing potential, willing to use effective contraception from the time of signing the informed consent form until 6 months after the last cell infusion (women of childbearing potential include premenopausal women and women within 2 years of postmenopausal time).\n8. Subjects must sign a written informed consent form.\n9. Subjects must be voluntary and able to comply with the scheduled treatment regimen, laboratory tests, follow-up, and other study requirements.\n\nExclusion Criteria:\n\n1. Pregnant and lactating females.\n2. Received any anti-tumor therapy (including but not limited to radiotherapy, chemotherapy, or immunotherapy) for pancreatic cancer within 28 days prior to enrollment.\n3. In the opinion of the investigator, the EUS technique poses undue risks to the subject, including but not limited to: - Previous EUS-FNA was technically deemed too difficult to perform; - Imaging showing multiple collateral vessels around or near the target tumor within the pancreas; - Presence of varicose veins near the target tumor. - If any of the above risk profiles become apparent after subject screening and\u002For enrollment, consideration should be given to withdrawal from the study prior to treatment.\n4. History of malignancy within 5 years, with the exception of basal cell carcinoma of the skin and carcinoma in situ of the cervix.\n5. Any other health condition by the judgment of the investigator would preclude participation in the study.",{"count":370,"type":20},20,[351],"This is a single-center, single-arm, open-label, dose-escalation clinical study to evaluate the safety and anti-tumor efficacy of intratumoral NKG2D CAR-NK cell injection guided by endoscopic ultrasound in the treatment of locally advanced pancreatic cancer.",[27],{"date":356,"type":32},{"date":376,"type":32},"2024-06-09",{"date":378,"type":20},"2026-06-30",{"name":341,"class":68},{"id":381,"slug":382,"hasResults":11,"nctId":383,"briefTitle":384,"officialTitle":385,"acronym":4,"eligibilityCriteria":386,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":387,"targetDuration":389,"studyType":139,"phases":4,"briefSummary":390,"conditions":391,"keywords":397,"overallStatus":185,"whyStopped":4,"lastUpdateSubmitDate":400,"lastUpdatePostDateStruct":401,"startDateStruct":403,"completionDateStruct":404,"leadSponsor":406,"locationsCount":4},"100567619","spanish-registry-of-quality-indicators-and-adverse-events-of-endoscopic-retrograde-cholangiopancreatography-100567619","NCT06670547","Spanish Registry of Quality Indicators and Adverse Events of Endoscopic Retrograde Cholangiopancreatography","Prospective and Multicenter Spanish Registry of Quality Indicators and Adverse Events of Endoscopic Retrograde Cholangiopancreatography","Inclusion Criteria:\n\nAll consecutive patients who have undergone an ERCP at participating centres from 1 November 2024 will be included. An ERCP will be considered to have been performed when an endoscope is introduced to access the duodenal papilla.\n\nThese included patients must meet all of the following criteria:\n\n* Over 18 years of age\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Under 18 years of age\n* Unavailability of informed consent\n* Impossibility of follow-up.",{"count":388,"type":20},3000,"30 Days","Endoscopic retrograde cholangiopancreatography (ERCP) is a technique which combines endoscopic and radiological vision and allows for therapeutic procedures on pathologies of the pancreas and bile duct.\n\nERCP is a generally well tolerated procedure, nonetheless it is a complex technique that has a higher frequency of complications compared to most endoscopic procedures that can even be life-threatening. These complications are related to patient characteristics, experience of the endoscopist performing the procedure, and specific factors to the technique. Due to its complexity, quality assurance, operator training and auditing are required to increase success and minimize complications.\n\nThere are quality indicators suggested by the main scientific societies in relation to technical aspects and complications, recommending their monitoring and auditing. Most endoscopy units lack records to monitor quality and complications, which prevents the assessment of quality and the identification of areas for improvement.\n\nGiven the lack of evidence of the quality of ERCP in the Spanish population, the investigators will be conducting a multicenter, national prospective study that will include subjects who undergo ERCP.\n\nPatient data and technical aspects of the procedure will be recorded and all included patients will be monitored to identify complications. The quality indicators obtained within the registry will be compared with those established by scientific societies and the relationship between complications and technical factors will be analyzed.",[392,393,394,395,114,27,396],"Choledocholithiasis","Choledocholithiasis With Acute Cholangitis","Cholangiocarcinoma","Sclerosing Cholangitis","Biliary Fistula",[398,399],"ERCP ADVERSE EVENTS","PERFORMANCE MEASURES","2024-10-31",{"date":402,"type":32},"2024-11-01",{"date":402,"type":20},{"date":405,"type":20},"2028-10-30",{"name":407,"class":68},"Germans Trias i Pujol Hospital",{"id":409,"slug":410,"hasResults":11,"nctId":411,"briefTitle":412,"officialTitle":413,"acronym":4,"eligibilityCriteria":414,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":415,"targetDuration":4,"studyType":21,"phases":417,"briefSummary":418,"conditions":419,"keywords":420,"overallStatus":185,"whyStopped":4,"lastUpdateSubmitDate":425,"lastUpdatePostDateStruct":426,"startDateStruct":428,"completionDateStruct":430,"leadSponsor":432,"locationsCount":4},"100545857","phase-4-clinical-study-of-huaier-granule-in-the-treatment-of-unresectable-pancreatic-cancer-100545857","NCT06387368","Clinical Study of Huaier Granule in the Treatment of Unresectable Pancreatic Cancer","Prospective, Multicenter, Randomized, Parallel Controlled Clinical Study on the Efficacy and Safety of Huaier Granules Combined With Capecitabine Versus Capecitabine Alone in the Treatment of Unresectable Pancreatic Cancer","Inclusion Criteria:\n\n* Age ≥ 18 years old, regardless of gender.\n* The patient has a clear evaluable lesion (RECIST 1.1) and is diagnosed with pancreatic adenocarcinoma through tissue or cellular pathology. Clinical evaluation suggests that radical surgical resection cannot be performed (due to jaundice and gastrointestinal obstruction caused by tumor compression, stent treatment or normal inclusion of biliary and gastrointestinal anastomosis can be performed).\n* Patients voluntarily give up conversion therapy, local radiation therapy, targeted immunity, and other programs.\n* The patient voluntarily choose chemotherapy, and the plan is to take capecitabine monotherapy orally.\n* ECOG score 0-3 points.\n* The patients voluntarily participate in and cooperates with all aspects of the research, including but not limited to cooperating with treatment and follow-up, cooperating with the researcher in data collection, not actively taking other treatments, and signing a written informed consent form.\n\nExclusion Criteria:\n\n* Known to be allergic to the components of Huaier granules or to avoid or use Huaier granules with caution (Huaier group).\n* Patients with difficulty swallowing, complete or incomplete gastrointestinal obstruction (excluding those who have undergone gastrointestinal stenting or diversion surgery due to tumor related gastrointestinal obstruction and have a normal diet, can be included in the study normally), active gastrointestinal bleeding, perforation, and other oral medication difficulties.\n* After actively reducing jaundice (including but not limited to bile duct\u002Fgallbladder puncture external drainage, nasobiliary duct external drainage, biliary stent internal drainage, biliary intestinal anastomosis internal drainage, etc.), the levels of aspartate aminotransferase, alanine aminotransferase, or total bilirubin are still 2.5 times higher than the upper limit of normal values.\n* History of merging with other malignant tumors.\n* Patients with concomitant myocardial infarction, cerebral infarction, and other thromboembolic diseases requiring surgical treatment.\n* Concomitant severe infection.\n* Child-Pugh C-grade liver function, renal function 2-5 grades (glomerular filtration rate\\\u003C90ml\u002Fmin).\n* Pregnant or lactating women or those planning to conceive.\n* The patient has received other traditional Chinese patent medicines and simple preparations with anti-tumor effect, chemotherapy or physical therapy in the past 4 weeks(including but not limited to compound cantharidin capsules, cinobufotalin capsules, Kangai injection, please refer to the drug instructions for details).\n* Suffering from serious mental illness or other reasons that the researcher deems unsuitable to participate in this study.",{"count":416,"type":20},488,[176],"This is a prospective, multicenter, randomized, open, parallel controlled clinical study to evaluate the efficacy and safety of Huaier Granules combined with capecitabine in the treatment of unresectable pancreatic cancer.",[27],[421,422,423,424],"Huaier Granules","Capecitabine","Unresectable Pancreatic Cancer","Efficacy and Safety","2024-04-23",{"date":427,"type":32},"2024-04-29",{"date":429,"type":20},"2024-05",{"date":431,"type":20},"2028-08",{"name":433,"class":68},"Xi'an Jiaotong University",{"id":435,"slug":436,"hasResults":11,"nctId":437,"briefTitle":438,"officialTitle":439,"acronym":4,"eligibilityCriteria":440,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":279,"enrollmentInfo":441,"targetDuration":4,"studyType":21,"phases":443,"briefSummary":444,"conditions":445,"keywords":447,"overallStatus":185,"whyStopped":4,"lastUpdateSubmitDate":453,"lastUpdatePostDateStruct":454,"startDateStruct":456,"completionDateStruct":458,"leadSponsor":460,"locationsCount":40},"100543835","phase-2-surufatinib-combined-with-gemcitabine-plus-nab-paclitaxel-in-locally-advanced-pancreatic-cancer-100543835","NCT06361030","Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer","An Exploratory Clinical Study of Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Patients With Locally Advanced Pancreatic Cancer","Inclusion Criteria:\n\n1. The subjects voluntarily joined the study and signed the informed consent, with good compliance and follow-up;\n2. Aged 18-75 years old (including 18 and 75 years old)\n3. male or female\n4. Histologically or cytologically confirmed adenocarcinoma of the pancreas\n5. Unresectable pancreatic cancer according to radiographic criteria (CT or MRI scans) or exploration( NCCN guidelines were referred): (1)The portal and superior mesenteric vein could not be reconstructed safely due to tumor invasion, venous occlusion, or involvement of a large area of the superior mesenteric vein jejunal branch (2)If pancreatic head\u002Funcinate tumor: tumor contacts superior mesenteric artery or celiac trunk artery \\>180 degrees. If pancreatic body tail tumor: tumor contacts the superior mesenteric artery or celiac trunk artery\\>180 degrees, and tumor contacts the celiac trunk artery and infiltrates the abdominal aorta.\n6. Without distant metastasis as defined by CT or MRI scan of the chest, abdomen and pelvis\n7. No prior systematic treatment for advanced pancreatic cancer\n8. At least one measurable lesion was required. (Response evaluation criteria in Solid Tumors, RECIST, version 1.1)\n9. ECOG performance status of 0 or 1\n10. Expected survival ≥12 weeks\n11. Acceptable organ and bone marrow function, laboratory values within 7 days prior to enrollment (no blood components, cell growth factors, albumin, or other corrective medications were allowed within 14 days prior to laboratory testing), as follows: (1)Blood routine: neutrophils ≥ 1.5 x 10⁹\u002FL, platelets ≥ 100 x 10⁹\u002FL, hemoglobin ≥ 9.0g\u002FdL; (2) Liver function: serum total bilirubin ≤ 1.5 x ULN; aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels ≤2.5 × ULN in subjects without liver metastases, AST and ALT levels ≤5 × ULN in subjects with documented liver metastases; (3) Renal function: serum creatinine ≤ 1.5 x ULN, or creatinine clearance (CCr) ≥ 50mL\u002Fmin; Urine protein \\< 2 +; if urine protein ≥2+ at baseline, 24-hour urine collection should be done and 24-hour urine protein \\< 1g; (4) Coagulation function: international normalized ratio (INR) and activated partial thromboplastin time (APTT) ≤ 1.5 times ULN.\n12. Female subjects of childbearing potential or male subjects whose sexual partner is a female of childbearing age should take effective contraceptive measures during the whole treatment period and 6 months after the last treatment.\n\nExclusion Criteria:\n\n1. Participants had a second primary malignancy detected prior to the first dose of study treatment, or has other malignancies diagnosed within 5 years prior to the first dose of study treatment, with the exception of radically treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and\u002For radically resected carcinoma in situ;\n2. Allergy to study medication or excipients\n3. With dysphagia or known malabsorption of drugs\n4. Have participated in any other drug clinical trial and received the corresponding trial drug within the previous 4 weeks. Or are participating in other clinical studies that may interfere with this study.\n5. Drug-uncontrolled hypertension；systolic blood pressure ≥140 mmHg and\u002For diastolic blood pressure ≥90 mmHg; History of hypertensive crisis or hypertensive encephalopathy.\n6. Patients with active gastric or duodenal ulcer, ulcerative colitis, intestinal obstruction, other gastrointestinal diseases, or active bleeding from unresectable tumors before enrollment, or other conditions that may cause gastrointestinal bleeding or perforation as judged by the investigator; Or have a history of bowel perforation or fistula and do not fully recover from surgery.\n7. Patients had a history of arterial or deep-vein thrombosis within 6 months before enrollment ，or had evidence or history of bleeding tendency, regardless of severity, within 2 months before enrollment.\n8. Stroke or transient ischemic attack occurred within 12 months before enrollment.\n9. Incomplete healing of skin wounds, surgical sites, trauma sites, severe mucosal ulcers, or fractures.\n10. Active bacterial, viral, or fungal infections requiring systemic treatment, defined as signs\u002Fsymptoms associated with the infection that persist and do not improve despite appropriate antibiotic, antiviral, and\u002For other treatments\n11. Known hepatitis B or C infection or a history of human immunodeficiency virus (HIV) infection ; Subjects receiving immunosuppressive or myelosuppressive drugs is considered to be associated with an increased risk of severe neutropenia complications by the investigators.\n12. Severe cardiovascular disease, including unstable angina or myocardial infarction, occurred within 6 months before enrollment; Clinically significant cardiovascular disease, including but not limited to acute myocardial infarction, severe\u002Funstable angina, or coronary artery bypass grafting within 6 months before enrollment; New York Heart Association (NYHA) classification of congestive heart failure \\>Grade 2; Ventricular arrhythmias requiring medical therapy; LVEF(left ventricular ejection fraction)\\\u003C50%. Electrocardiogram (ECG) corrected QT interval ≥480 msec.\n13. Clinically significant ascites\n14. Clinically significant electrolyte disturbances.\n15. Severe mental illness that may compromise the safety of the subjects or the integrity of the study data.\n16. Any clinical or laboratory abnormalities or adherence that were deemed by the investigator to be inappropriate for participation in the trial.",{"count":442,"type":20},40,[24],"To evaluate the efficacy and safety of surufatinib combined with gemcitabine plus nab-paclitaxel in patients with locally advance d pancreatic cancer",[142,27,446],"Pancreatic Ductal Adenocarcinoma, PDAC",[448,449,450,451,452],"Pancreatic ductal adenocarcinoma","surufatinib","surgical conversion","gemcitabine","nab-paclitaxel","2024-04-07",{"date":455,"type":32},"2024-04-11",{"date":457,"type":20},"2024-06-01",{"date":459,"type":20},"2027-06-01",{"name":461,"class":68},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",{"id":463,"slug":464,"hasResults":11,"nctId":465,"briefTitle":466,"officialTitle":467,"acronym":4,"eligibilityCriteria":468,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":303,"enrollmentInfo":469,"targetDuration":4,"studyType":21,"phases":471,"briefSummary":472,"conditions":473,"keywords":474,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":480,"lastUpdatePostDateStruct":481,"startDateStruct":483,"completionDateStruct":485,"leadSponsor":486,"locationsCount":40},"100471844","ablative-carbon-ion-radiotherapy-with-pencil-beam-scanning-for-locally-advanced-unresectable-pancreatic-cancer-100471844","NCT05424159","Ablative Carbon Ion Radiotherapy With Pencil Beam Scanning for Locally Advanced Unresectable Pancreatic Cancer","Prospective Phase II Clinical Trial of Ablative Carbon Ion Radiotherapy With Pencil Beam Scanning Using Simultaneous Integrated Boost for Locally Advanced Unresectable Pancreatic Cancer","Inclusion Criteria:\n\n1. Have the ability to sign the written informed consent;\n2. Ductal adenocarcinoma of the pancreas confirmed by histopathology or cytopathology;\n3. Distant metastasis was excluded by imaging assessment (PET-CT, cranial MRI), and was defined as locally advanced unresectable according to NCCN Guidelines Version 2022.1, that is, T4N0-2M0, Stage III (AJCC\u002FUICC Version 8);\n4. The maximum diameter of pancreatic primary lesion and positive lymph node ≤7cm;\n5. Pancreas primary lesion or positive lymph node did not invade digestive tract (stomach, duodenum and small intestine);\n6. Eastern Cooperative Oncology Group (ECOG) performance score 0-1;\n7. Adequate bone marrow function (neutrophil count ≥1.5×109\u002FL, platelet count ≥100×109\u002FL, hemoglobin ≥10.0g\u002FdL);\n8. Adequate liver function (total bilirubin \\\u003C1.5 times the upper limit of normal value, aminotransferase \\\u003C2.5 times the upper limit of normal value);\n9. Adequate renal function (serum creatinine \\\u003C2mg\u002FdL, or creatinine clearance \\>50mL\u002Fmin).\n\nExclusion Criteria:\n\n1. Multiple primary pancreatic lesions (\\>1);\n2. Tumor invaded the adjacent digestive tract;\n3. Radiation therapy history;\n4. Other local treatments history for pancreatic cancer, such as HIFU and irreversible electroporation;\n5. The irradiation dose of organs at risk cannot reach the dose constraint;\n6. Other malignant tumors history;\n7. Inability to understand the purpose of treatment or unwillingness\u002Finability to sign informed consent.",{"count":470,"type":20},48,[79],"The aim of this study is to investigate the clinical efficacy and safety of ablative carbon ion radiotherapy for locally advanced unresectable pancreatic cancer with pencil beam scanning and simultaneous integrated boost (SIB) technology.",[27],[475,476,477,478,479],"Locally advanced unresectable pancreatic cancer","Carbon ion radiotherapy","Phase II clinical trial","Ablative dose","Optimized linear energy transfer","2023-11-30",{"date":482,"type":32},"2023-12-07",{"date":484,"type":32},"2022-07-01",{"date":219,"type":20},{"name":487,"class":68},"Shanghai Proton and Heavy Ion Center",{"id":489,"slug":490,"hasResults":11,"nctId":491,"briefTitle":492,"officialTitle":493,"acronym":4,"eligibilityCriteria":494,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":495,"targetDuration":4,"studyType":21,"phases":497,"briefSummary":498,"conditions":499,"keywords":4,"overallStatus":185,"whyStopped":4,"lastUpdateSubmitDate":500,"lastUpdatePostDateStruct":501,"startDateStruct":503,"completionDateStruct":505,"leadSponsor":507,"locationsCount":4},"100500917","pancreatic-cancer-dynamic-assessment-at-all-stages-of-treatment-100500917","NCT05802485","PANCREATIC CANCER: DYNAMIC ASSESSMENT AT ALL STAGES OF TREATMENT","PANCREATIC CANCER: DYNAMIC ASSESSMENT AT ALL STAGES OF TREATMENT: PANDORE-PANC-IPC 2021-082","Inclusion Criteria:\n\n* Non-metastatic pancreatic adenocarcinoma that is not immediately resectable (borderline and locally advanced tumors according to the NCCN 2020 classification)\n* No previous treatment with surgery or chemotherapy\n* Age \\> 18 years\n* General condition WHO 0-2 (patient whose general condition can allow medical treatment or surgery)\n* Therapeutic management at the Paoli-Calmettes Institute\n* Signature of the informed consent specific to the PANDORE-PANC study\n* Patient affiliated to a social security system or benefiting from such a system\n\nExclusion Criteria:\n\n* Metastatic disease\n* Pancreatic tumor of a histological type other than adenocarcinoma\n* Other tumor under treatment or for which treatments have been completed for \\\u003C 1 year\n* Pregnant or breastfeeding women\n* Person in an emergency situation\n* Person of legal age under legal protection (guardianship, curatorship or safeguard of justice) or unable to give consent.",{"count":496,"type":20},300,[79],"The study consists of a 25 ml blood sample collection:\n\n* Before the start of treatment\n* Approximately 2 months after the start of induction chemotherapy\n* At the end of induction chemotherapy\n* Prior to local treatment (radiotherapy, surgery)\n* At the time of tumor progression\n\nCollection of tumor material:\n\n* During the initial diagnostic biopsy\n* On the operating room in case of surgery\n* At tumor biopsy in case of recurrence or progression (optional) As well as the completion of a questionnaire at inclusion.",[27],"2023-03-27",{"date":502,"type":32},"2023-04-06",{"date":504,"type":20},"2023-04-30",{"date":506,"type":20},"2029-02-01",{"name":508,"class":68},"Institut Paoli-Calmettes"]